by Clinical Neuropsychologist | Tuesday, November 26, 2024 | Dementia
Abstract INTRODUCTION Non-pharmacological interventions may offer significant benefits to the quality of life for persons with primary progressive aphasia (PPA) and their care partners but have lacked efficacy trials. To help fill the efficacy gap, we provide the...
by Clinical Neuropsychologist | Tuesday, November 26, 2024 | Dementia
Abstract INTRODUCTION Alterations in locus coeruleus’ (LC) metabolic turnover are associated with Alzheimer’s disease (AD)-pathology and cognitive impairment. However, the evolution of these changes across disease stages and their functional relevance remains...
by Clinical Neuropsychologist | Tuesday, November 26, 2024 | Dementia
Abstract The presence of multiple pathologies is the largest predictor of dementia. A major gap in the field is the in vivo detection of mixed pathologies and their antecedents. The Alzheimer’s Disease Research Centers (ADRCs) are uniquely positioned to address...
by Clinical Neuropsychologist | Tuesday, November 26, 2024 | Dementia
Abstract INTRODUCTION Alzheimer’s disease (AD) is a highly heritable disease (60%–80%). Amyloid beta (Aβ) 42/40, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) are plasma biomarkers for AD. Clinical biomarker research would be served...
by Clinical Neuropsychologist | Monday, November 25, 2024 | Dementia
Abstract INTRODUCTION Despite extensive studies on mixed neuropathologies, data from China are limited. This study aims to fill this gap by analyzing brain samples from Chinese brain banks. METHODS A total of 1142 brains from six Chinese brain banks were examined...
by Clinical Neuropsychologist | Saturday, November 23, 2024 | Dementia
Abstract INTRODUCTION Studies have correlated living close to major roads with Alzheimer’s disease (AD) risk. However, the mechanisms responsible for this link remain unclear. METHODS We exposed olfactory mucosa (OM) cells of healthy individuals and AD patients...
